An indirect treatment comparison of efficacy and health-related quality of life following treatment with idecabtagene vicleucel versus belantamab mafodotin in triple-class exposed relapsed/refractory patients with multiple myeloma

  1. Rodríguez Otero, P.
  2. Towle, K.
  3. Cope, S.
  4. Caisip, C.
  5. Davies, F.E.
  6. Delforge, M.
  7. Weisel, K.
  8. Marshall, T.S.
  9. Karampampa, K.
  10. Ayers, D.
  11. Mojebi, A.
  12. Braverman, J.
  13. Farrell, J.
  14. Dhanda, D.
Revue:
Leukemia and Lymphoma

ISSN: 1029-2403 1042-8194

Année de publication: 2023

Volumen: 64

Número: 11

Pages: 1864-1869

Type: Lettre

DOI: 10.1080/10428194.2023.2235042 GOOGLE SCHOLAR lock_openAccès ouvert editor

Objectifs de Développement Durable